Resistance Training in the ICU Improves Muscle, Function, and Survival — HMB Adds Only Modest Benefit
Posted inCritical Care news Rehabilitation Medicine

Resistance Training in the ICU Improves Muscle, Function, and Survival — HMB Adds Only Modest Benefit

A multicenter 2×2 factorial RCT in 266 critically ill adults shows that in‑ICU resistance training improves discharge physical function, muscle mass, patient‑reported outcomes, and lowers 6‑ and 12‑month mortality; HMB supplementation produced only small gains in phase angle and fatigue with no additive effect.
Nationwide Prevention Programme in Australia Associated with Lower Preterm and Early‑Term Singleton Births: National and Hospital‑Level Results
Posted innews OB/GYN & Women's Health Public Health

Nationwide Prevention Programme in Australia Associated with Lower Preterm and Early‑Term Singleton Births: National and Hospital‑Level Results

A multifaceted national preterm birth prevention programme in Australia was associated with a modest national decrease in late preterm births and, after a hospital collaborative, a substantial reduction in early‑term births in participating centres, without increasing preterm rates.
Multi‑armoured oncolytic HSV‑1 (VG161) shows immune remodelling and promising activity in advanced intrahepatic cholangiocarcinoma: pooled early‑phase insights
Posted innews Oncology

Multi‑armoured oncolytic HSV‑1 (VG161) shows immune remodelling and promising activity in advanced intrahepatic cholangiocarcinoma: pooled early‑phase insights

Pooled Phase I/IIa data (n=24) indicate intratumoural VG161 is well tolerated in advanced intrahepatic cholangiocarcinoma, elicits local and systemic immune activation (APC recruitment, CD8+ T‑cell activation, M2 macrophage depletion) and suggests clinical benefit — including signals versus historical second‑line FOLFOX — warranting randomized validation.
Location Alone Shouldn’t Drive ESD: French Registry Finds Similar Submucosal Cancer Rates in Large Rectal and Colonic Non‑Pedunculated Polyps
Posted inGastroenterology news

Location Alone Shouldn’t Drive ESD: French Registry Finds Similar Submucosal Cancer Rates in Large Rectal and Colonic Non‑Pedunculated Polyps

A multicentre French ESD registry found that, after adjusting for size and morphology, large non‑pedunculated rectal polyps do not have higher rates of submucosal invasive cancer than equivalent colonic lesions; technical outcomes of ESD were comparable, with a trend to higher complications in the colon.
PDE5A-Positive Cancer-Associated Fibroblasts Drive Immune Exclusion in Gastric Cancer — Therapeutic Rationale for Combining PDE5 Inhibition with LAG3 Blockade
Posted inGastroenterology news Oncology

PDE5A-Positive Cancer-Associated Fibroblasts Drive Immune Exclusion in Gastric Cancer — Therapeutic Rationale for Combining PDE5 Inhibition with LAG3 Blockade

Single‑cell and spatial profiling identify a PDE5A+ CAF subset that remodels stroma, activates PI3K/AKT/mTOR–CXCL12 signaling, and recruits exhausted LAG3+ CD8 T cells, promoting immune exclusion in gastric cancer. Vardenafil plus LAG3 blockade restores antitumour immunity in preclinical models, supporting biomarker‑driven combination trials.
GLP‑1 Receptor Agonists Provide Greatest MACE Reduction in Type 2 Diabetes — Evidence from a Large US Comparative-Effectiveness Study
Posted inCardiology Diabetes & Endocrinology news

GLP‑1 Receptor Agonists Provide Greatest MACE Reduction in Type 2 Diabetes — Evidence from a Large US Comparative-Effectiveness Study

In a 241,981-patient emulated trial using modern causal methods, sustained GLP‑1RA use yielded the lowest 2.5‑year MACE risk, followed by SGLT2is, sulfonylureas, and DPP4is; the GLP‑1RA advantage over SGLT2is was greatest in older adults and those with ASCVD, HF, or kidney impairment.
Baseline SGLT2 Inhibitor Use Associated with Lower Risk of Sepsis-Induced Cardiomyopathy and Improved Outcomes in Type 2 Diabetes: Insights from a Large Propensity-Matched Cohort
Posted inCardiology Critical Care news

Baseline SGLT2 Inhibitor Use Associated with Lower Risk of Sepsis-Induced Cardiomyopathy and Improved Outcomes in Type 2 Diabetes: Insights from a Large Propensity-Matched Cohort

A large propensity-matched cohort study found that baseline SGLT2 inhibitor use versus DPP4 inhibitor therapy in adults with type 2 diabetes and infection was associated with lower 30-day sepsis-induced cardiomyopathy and improved 1-year mortality and cardiovascular outcomes; residual confounding and safety considerations warrant prospective trials.